TRANSMITTAL FORM  (to be used for all correspondence after initial formula in the correspondence after initial	Application Number  Filing Date First Named Inventor  Art Unit Examiner Name  Attorney Docket Number	Approved for use through 04/30/2003. OMB 0651-003: ent and Trademark Office; U.S. DEPARTMENT OF COMMERCE tion of information unless it displays a valid OMB control number 10/623,972  July 21, 2003  Chen, et al.
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Add  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Remarks  References B1 to B5 and C1 to C21	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
Firm or Individual Signature	TURE OF APPLICANT, ATTORN	LI, ON ACENT
	ERTIFICATE OF TRANSMISSION Insmitted to the USPTO or deposited with the Ur Patents, P.O. Box 1450, Alexandria, VA 223	United States Postal Service with sufficient postage as first class

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

Date

October 22, 2003





# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Chen, et al.

Serial No. 10/623,972, filed July 21, 2003

(Ref. No. 21266 US1)

For: PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY

#### INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 October 22, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1 to B5 and C1-C21 listed on Form PTO-1449 are enclosed. Copies of documents A1-A6 are not enclosed as they are U.S. patents.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/623,972 Filed: July 21, 2003

Applicants bring to the Examiner's attention that co-owned U.S. Patent 6,150,373 (Harris, et al.) (document A1) is involved in an interference (Interference No. 104,798) with the U.S. application on which WO 99/61444 (document B2) is based. In the course of this interference the documents listed below were either cited or located by applicants. Applicants bring these documents to the Examiner's attention for purposes of completion. While the undersigned believes that U.S. Patent No. 6,150,373 and WO 99/61444 are the most relevant references, the documents available as a result of the interference are also herein cited for completion.

# <u>Documents Located As Part of Interference No. 104,798</u>

### **U.S. Patent Documents**

<b>A2</b>	2,949,466	Hoefle, et al.	08/16/1960
А3	4,886,807	Kitamura, et al.	12/12/1989
<b>A4</b>	3,939,084	Sullivan	02/17/1976
<b>A5</b>	4,425,346	Horlington	01/10/1984

#### **Foreign Patent Documents**

ВЗ	WO 02/18380 A1	F.Hoffmann-La Roche Inc.	03/07/2002
B4	WO 01/64679 A1	SmithKline Beecham Corp.	09/07/2001

#### Non Patent Literature Documents

C5 Masquelin et al., *Helvetica Chimica Acta*, Vol. 81 (1998) pgs. 646-659

Devi, et al., *Indian Journal of Heterocyclic Chemistry*, Vol. 7, January – March, 1998, pgs. 193-196

Serial No. 10/623,972 Filed: July 21, 2003

## Non Patent Literature Documents - Continued

- C7 Tominaga et al., *Chemical & Pharmaceutical Bulletin*, Vol. 32, No. 1, January 1984, pgs. 122-129
- C8 Tominaga et al., *Heterocycles*, Vol. 12, No. 4, 1979, pgs. 503-504
- Marsh et al., Chemical Communications 1996, pgs. 1527-1528
- **C10** *Z. Chem.* 20 Jg (1980) Heft. 11, pgs. 412-413
- C11 Cappuccino et al., Cancer Research Vol. 24, August 1964, pgs. 1243-1248
- C12 Chatterjee et al., *J. Sci. Industr. Res.*, Vol. 17B, February, 1958, pgs. 63-70
- C13 Chatterjee et al., *J. Sci. Industr. Res.*, Vol. 18B, July, 1959, pgs. 272-278
- **C14** Graboyes et al., *Pteridines X.*, Vol. 11 January 6, 1968, pgs. 568-573
- C15 Grohe et al., *Liebigs Ann. Chem*, 1974, pgs. 2066-2073
- Gulevskaya et al., *Chemistry of Heterocyclic Compounds*, Vol. 30, No. 9, 1994, pgs. 1083-1091
- C17 Hirota et al., *J. Chem. Soc. Perkin Trans.*, 1, 1990, pgs. 123-128
- C18 Srivastava, et al., Combinatorial Chemistry & High Throughout Screening, 1999, 2, pgs. 33-37
- C19 Taylor et al., Pyrimido [4,5-D]Pyrimidines, Vol. 82, pgs. 5711-5718
- C20 Wamhoff et al., *Heterocycles*, Vol. 35, No. 2, 1993, pgs. 1055-1066
- M. Hirota et al., "A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]-Pyrimidine-2,4-diones", Synthesis, pgs. 589-590 (1984)

Serial No. 10/623,972

Filed: July 21, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)
Patricia S. Rocha-Tramaloni

(Reg. No. 31,054) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-2441 Telefax: (973) 235-2363

**Enclosures** 

135078

	Substitute for	or form	1449	VP1
INFORM	TION	DIC	OT.	^

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)
of 2

Complete if Known			
Application Number	10/623,972		
Filing Date	July 21, 2003		
First Name Inventor	Chen, et al.		
Attorney Docket Number	21266 US1		

## **U.S. PATENT DOCUMENTS**

· · ·				J.D. I ALE	MI DOCUMENTO		
Examiner Initials'	Initials' No.1 Ki		Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited document MM-DD-YY	nt	
	A1	6,150,	373		Harris, et al.	11/21/2000	
	A2	2,949,	466		Hoefle, et al.	08/16/1960	
	<b>A3</b>	4,886,	807		Kitamura, et al.	12/12/1989	
	A4	3,939,	084		Sullivan	02/17/1976	
	A5	4,425,	346		Horlington	01/10/1984	
	A6	6,451,804			Dunn, et al.	09/17/2002	
		•	FOI	REIGN PA	TENT DOCUMENTS		
Examiner Initials'	Cite No.'	Foreign Office <sup>3</sup>	Patent Docur	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
	B1	WO 9	8/24432		Sugen, Inc.	06/11/1998	
	B2	WO 9	9/61444		Warner-Lambert Company	12/02/1999	
	В3	WO 02	2/18380 A1		F.Hoffmann-La Roche AG	03/07/2002	
	B4	WO 0	1/64679 A1		SmithKline Beecham Corp.	09/07/2001	
	B5	WO 0	1/29041 A1		F.Hoffmann-La Roche AG	04/26/2001	

# NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	Hennequin, L. F. et al., J. Med. Chem. 2002, Vol. 45(6) pgs. 1300-1312	
	C2	Klohs W. E. et al., Current Opinion in Biotechnology 1999, Vol. 10, pgs. 544-549	
	C3	Ansel, H. et al., <i>Pharmaceutical Dosage Forms &amp; Drug Delivery Systems</i> 6 <sup>th</sup> Ed. 1995, pg. 196	
	C4	J. Alexander, et al., J. Med. Chem. 1988, Vol. 31, pgs. 318-322	
	C5	Masquelin et al., Helvetica Chimica Acta, Vol. 81 (1998) pgs. 646-659	
	C6	Devi, et al., <i>Indian Journal of Heterocyclic Chemistry</i> , Vol. 7, January – March, 1998, pgs. 193-196	
	C7	Tominaga et al., Chemical & Pharmaceutical Bulletin, Vol. 32, No. 1, January 1984, pgs. 122-129	
	C8	Tominaga et al., Heterocycles, Vol. 12, No. 4. 1979, pgs. 503-504	
***************************************	<b>C9</b>	Marsh et al., Chemical Communications, 1996, pgs. 1527-1528	
	C10	Z. Chem. 20 Jg (1980) Heft. 11, pgs. 412-413	
	C11	Cappuccino et al., Cancer Research, Vol. 24, August 1964, pgs. 1243-1248	
	C12	Chatterjee et al., J. Sci. Industr. Res., Vol. 17B, February, 1958, pgs. 63-70	
	C13	Chatterjee et al., J. Sci. Industr. Res., Vol. 18B, July, 1959, pgs. 272-278	
	C14	Graboyes et al., Pteridines X., Vol. 11 January 6, 1968, pgs. 568-573	
	C15	Grohe et al., Liebigs Ann. Chem., 1974, pgs. 2066-2073	

	Su	ibstitute f	or form 1449A/PTO	Complete if Known		
55	INFORMAT	ΓION	DISCLOSURE	Application Number	10/623,972	
\ \ <u>\</u>	STATEME	NT B	Y APPLICANT	Filing Date	July 21, 2003	
30		al shee	ts if necessary)	First Name Inventor	Chen, et al.	
Sheet	t 2	of	2	Attorney Docket Number	21266 US1	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C16	Gulevskaya et al., Chemistry of Heterocyclic Compounds, Vol. 30, No. 9, 1994, pgs. 1083-1091	
	C17	Hirota et al., J. Chem. Soc. Perkin Trans. 1, 1990, pgs. 123-128	
	C18	Srivastava, et al., Combinatorial Chemistry & High Throughout Screening, 1999, 2, pgs. 33-37	
	C19	Taylor et al., Pyrimido [4,5-D]Pyrimidines, Vol. 82, pgs. 5711-5718	
	C20	Wamhoff et al., <i>Heterocycles</i> , Vol. 35, No. 2, 1993, pgs. 1055-1066	
	C21	M. Hirota et al., "A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]- Pyrimidine-2,4-diones", Synthesis, pgs. 589-590 (1984)	
Examiner Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

The Advinces of the communication to applicant.

1 Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Stind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation or abstract is attached.